한글목차

DOPTELET은 트롬보포이에틴 수용체 작용제이며, 기존 치료로 충분한 효과를 얻지 못한 만성 ITP 성인 환자의 혈소판 감소증 치료에 적응증을 가지고 있습니다.

미국에서는 만성 ITP에 수반되는 혈소판감소증에 대한 승인을 받았으며, 유럽연합(EU)의 약물사용자문위원회(CHMP)는 다른 치료제에 내성이 있는 성인 환자의 원발성 만성 ITP에 대해 긍정적인 의견을 채택했습니다. 또한 기증자 조혈모세포 이식 후 ITP 및 혈소판감소증 소아 환자를 대상으로 평가 중입니다.

아바트롬보파그는 경구에서 생물학적으로 이용 가능한 저분자 TPO 수용체 작용제이며, 골수 전구세포에서 거핵세포의 증식 및 분화를 자극하여 혈소판 생성을 증가시킵니다. 아바트롬보팍은 TPO 수용체에 결합할 때 TPO와 경쟁하지 않으며, 혈소판에 대한 TPO와 시너지 효과를 발휘합니다.

주요 7개국의 DOPTELET 시장에 대해 조사했으며, 시장의 개요와 2023-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 면역성 혈소판 감소증(ITP)에 대한 DOPTELET의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제상 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 DOPTELET 시장 평가

• ITP에 대한 DOPTELET의 시장 전망
• 주요 7개국 시장 분석
  • 주요 7개국에서 ITP에 대한 DOPTELET의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"DOPTELET Drug Insight and Market Forecast - 2032" ” report provides comprehensive insights about DOPTELET for immune thrombocytopenic purpura (ITP) in the seven major markets. A detailed picture of the DOPTELET for ITP in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the DOPTELET for ITP. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DOPTELET market forecast analysis for ITP in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ITP.

Drug Summary:

DOPTELET is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to previous treatment.

For thrombocytopenia with chronic ITP, it is approved in the US. In the EU, Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for primary chronic ITP in adult patients who are refractory to other treatments.

It is also being evaluated in pediatric subjects with ITP and thrombocytopenia after donor hematopoietic stem cell transplant.

Dosage

Chronic ITP: Initiate DOPTELET at 20 mg (one tablet) once daily. Adjust the dose or frequency of dosing to maintain a platelet count greater than or equal to 50 × 109/L. Do not exceed 40 mg per day.

Mechanism of action

Avatrombopag is an orally bioavailable, small-molecule TPO receptor agonist that stimulates the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DOPTELET description, mechanism of action, dosage and administration, research and development activities in immune thrombocytopenic purpura (ITP).
• Elaborated details on DOPTELET regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DOPTELET research and development activities in ITP across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DOPTELET.
• The report contains forecasted sales of DOPTELET for ITP till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ITP.
• The report also features the SWOT analysis with analyst views for DOPTELET in ITP.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DOPTELET Analytical Perspective by DelveInsight

In-depth DOPTELET Market Assessment

This report provides a detailed market assessment of DOPTELET for immune thrombocytopenic purpura (ITP) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

DOPTELET Clinical Assessment

The report provides the clinical trials information of DOPTELET for ITP covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for immune thrombocytopenic purpura (ITP) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DOPTELET dominance.
• Other emerging products for ITP are expected to give tough market competition to DOPTELET and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DOPTELET in ITP.
• Our in-depth analysis of the forecasted sales data of DOPTELET from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DOPTELET in ITP.

Key Questions:

• What is the product type, route of administration and mechanism of action of DOPTELET?
• What is the clinical trial status of the study related to DOPTELET in immune thrombocytopenic purpura (ITP) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DOPTELET development?
• What are the key designations that have been granted to DOPTELET for ITP?
• What is the forecasted market scenario of DOPTELET for ITP?
• What are the forecasted sales of DOPTELET in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to DOPTELET for ITP?
• Which are the late-stage emerging therapies under development for the treatment of ITP?

Table of Contents

1. Report Introduction

2. DOPTELET Overview in ITP

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. DOPTELET Market Assessment

• 5.1. Market Outlook of DOPTELET in ITP
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of DOPTELET in the 7MM for ITP
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of DOPTELET in the United States for ITP
  • 5.3.2. Market Size of DOPTELET in Germany for ITP
  • 5.3.3. Market Size of DOPTELET in France for ITP
  • 5.3.4. Market Size of DOPTELET in Italy for ITP
  • 5.3.5. Market Size of DOPTELET in Spain for ITP
  • 5.3.6. Market Size of DOPTELET in the United Kingdom for ITP
  • 5.3.7. Market Size of DOPTELET in Japan for ITP

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options